All News

Crinecerfont approval makes available the first new treatment for the life-altering endocrine disorder in more than 70 years, according to Neurocrine Biosciences.

A phase 1b and Phase 2 study are up next for the novel potential MDD treatment.

Intra-Cellular Therapies submitted an sNDA to the FDA for lumateperone for the treatment of MDD in adults as as adjunctive therapy to antidepressants.

Your daily dose of the clinical news you may have missed.

The new nonsteroidal topical treatments for atopic dermatitis are targeted and modify the disease process, explains thought leader Shahriari in this year's video series.

Your daily dose of the clinical news you may have missed.

Moderna paused clinical research on the pediatric shot indefinitely in September after reports in July of severe adverse reactions in infants aged 5 to 8 months.

Upadacitinib (15 and 30 mg) was evaluated in adolescents with moderate to severe AD aged 12 to 17 years, with and without topical corticosteroids.

Your daily dose of the clinical news you may have missed.

An analysis of patient reported outcome measures from 3 pivotal phase 3 RCTs of atogepant 60 mg demonstrates efficacy across functional domains as well as for migraine prevention.

An MDF stethoscope with leopard print tubing? A digital highlighter/scanner that translates and talks back? Check out these and 8 more uncommon gifts for health care professionals.

Your daily dose of the clinical news you may have missed.

The Prescription Drug User Fee Act date is set for May 7, 2025.

Your daily dose of the clinical news you may have missed.

Americans' rating of the quality of health care available in the US has hit its lowest in 24 years, according to a new Gallup survey; here's what they think.

Your daily dose of the clinical news you may have missed.

The CGRP inhibitor fremanezumab reduced both monthly migraine and monthly headache days among children aged 6 to 17 years with a favorable safety profile.

Your daily dose of the clinical news you may have missed.